Novartis spinout resTORbio reverse merges with T cell biotech after big PhIII failure
The end of their lead program will, it turns out, spell the end for Novartis spinout resTORbio.
Shares for the once well-funded anti-aging biotech crumbled after its lead program failed a Phase III trial last year. The company said they would shift focus to an early stage Parkinson’s candidate, but that looked like a long shot at the time, and today, the company announced they will reverse merge with Adicet Bio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
